Please activate JavaScript!
Please install Adobe Flash Player, click here for download


20. Eisert V., Kreutz M., Becker K., Konigs C., Alex U., Rubsamen-Waigmann H., Andreesen R., von Briesen H., 2001. Analysis of cellular factors influencing the replication of human immunodeficiency virus type I in human macrophages derived from blood of different healthy donors. Virology 286:31–44. 21. Elvin S.J., Williamson E.D., Scott J.C., Smith J.N., Perez D.L., Chilla S., Clapham P., Pfeffer K., Schlondorff D., Luckow B., 2004. Evolutionary genetics: Ambiguous role of CCR5 in Y. pestis infection. Nature 430:1. 22. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D., 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2:303–308. 23. Fortin A., Stevenson M.M., Gros P., 2002. Susceptibility to malaria as a complex trait: big pressure from a tiny creature. Hum. Mol. Genet. 11:2469–2478. 24. Furrer H., Telenti A., 2004. Bereit für neue medizinische Herausforderung: die Schweizerische «Genetics HIV Cohort». Ther Umsch in press. 25. Ganesh L., Burstein E., Guha-Niyogi A., Louder M.K., Mascola J.R., Klomp L.W., Wijmenga C., Duckett C.S., Nabel G.J., 2003. The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature 426:853–857. 26. Gao G., Guo X., Goff S.P., 2002. Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science 297:1703–1706. 27. Goff S.P., 2003. Death by deamination: a novel host restriction system for HIV-1. Cell 114:281–283. 28. Greene W.C., Peterlin B.M., 2002. Charting HIV’s remarkable voyage through the cell: Basic science as a passport to future therapy. Nat. Med. 8:673–680. 29. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H., 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803–809. 30. Hatziioannou T., Cowan S., Goff S.P., Bieniasz P.D., Towers G.J., 2003. Restriction of multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 22:385–394. 31. Havlir D., Eastman S., Gamst A., Richman D.D., 1996. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreat- ed patients. J Virol 70:7894–7899. 27